Date: 28th March, 2014 (Friday)
Time: 2:30 – 5:00 pm (registration starts at 2:15 pm; refreshment will be served after the event)
Venue: Meeting Room 3&4, G/F, InnoCentre, Kowloon Tong
Judging from the past years’ experience, most of the participating projects were reckoned to have great potential for further development into new drug candidates. To stand a better chance of realizing the potential of all upcoming projects, it is crucial that their presentations not only give the right sort of information, but also put in perspective the interests and concerns of the audience, namely industry professionals and investors.
In view of this, Dr. Daniel LEE (Head, Biotechnology Cluster) and Mr. Constant TANG (Consultant, Acceleration Programme), are pleased to host a symposium in the afternoon of 28th March (Friday) at InnoCentre to share with you their insights in the issue as they both have acquired much work experience in the pharmaceuticals and investment sectors respectively.
You are, therefore, cordially invited to attend this half-day symposium. For enquiries, please contact Mr. Paul Chan at 2629 6881 or firstname.lastname@example.org / Mr. Eddie Ching at 2629 6872 or email@example.com
Brief bio of speakers:
Mr. Daniel LEE is a clinical biochemist by training and obtained his PhD in Pathology at the University of Hong Kong. He has worked in the pharmaceutical industry for over 25 years and serviced JNJ, Biogen, GSK China and lately served as General Manger and Head of site for Roche Pharma R&D China from 2010. He has published over 60 papers and owned co-inventorship on 13 patents. His work was associated with multiple pharmaceutical products. He consults for multiple international companies, investment funds and an active reviewer for scientific journals and government and private funding agencies. He is currently Head of Biotech Cluster at the Hong Kong Science and Technology Park Inc., an Honorary Professor of the Faculty of Medicine, The University of Hong Kong and a Visiting Scholar of Division of Life Science, The Hong Kong University of Science of Technology.
Mr. Constant TANG was a Managing Director of Cowen and Company Asia, where he was head of the Asia Health Care investment banking practice. He has advised clients on US IPOs, M&A and Private Placements and has extensive experience with the VC community in Asia. Prior to Cowen, Mr. Tang was an equity research analyst at Lehman Brothers Asia. Mr. Tang holds an MBA from the Richard Ivey School of Business in Canada, and a Bachelor of Applied Science (Electrical Engineering) from the University of Waterloo in Canada. He is a CFA Charterholder and a Licensed Professional Engineer.